MNDA Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 0.2 mg/ml

MNDA Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 15 amino acids near the center of MNDA.

  Source: Synthetic

  (Accession #: P41218.1)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: MNDA
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP3-18135. For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for MNDA Antibody Blocking Peptide

• myeloid cell nuclear differentiation antigen
• PYHIN3

Background

The myeloid cell nuclear differentiation antigen (MNDA) is detected only in nuclei of cells of the granulocyte-monocyte lineage. A 200-amino acid region of human MNDA is strikingly similar to a region in the proteins encoded by a family of interferon-inducible mouse genes, designated Ifi-201, Ifi-202, and Ifi-203, that are not regulated in a cell- or tissue-specific fashion. The 1.8-kb MNDA mRNA, which contains an interferon-stimulated response element in the 5-prime untranslated region, was significantly upregulated in human monocytes exposed to interferon alpha. MNDA is located within 2,200 kb of FCER1A, APCS, CRP, and SPTA1. In its pattern of expression and/or regulation, MNDA resembles IFI16, suggesting that these genes participate in blood cell-specific responses to interferons.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: MNDA